Wells Fargo & Company Issues Pessimistic Forecast for Avantor (NYSE:AVTR) Stock Price

Avantor (NYSE:AVTR) had its price objective lowered by Wells Fargo & Company from $30.00 to $28.00 in a research report sent to investors on Monday morning, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

A number of other equities analysts also recently commented on the stock. Robert W. Baird dropped their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday. Citigroup downgraded Avantor from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $30.00 to $23.00 in a report on Wednesday, July 10th. Barclays dropped their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Stifel Nicolaus lifted their price objective on Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a report on Monday, July 29th. Finally, TD Cowen increased their target price on shares of Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, July 29th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.57.

Avantor Trading Down 0.3 %

NYSE AVTR opened at $22.45 on Monday. The stock has a market cap of $15.25 billion, a PE ratio of 57.56, a PEG ratio of 2.93 and a beta of 1.33. Avantor has a 12 month low of $17.06 and a 12 month high of $28.00. The company’s 50-day moving average price is $25.32 and its 200-day moving average price is $24.21. The company has a current ratio of 1.59, a quick ratio of 1.05 and a debt-to-equity ratio of 0.89.

Insider Buying and Selling at Avantor

In other news, CAO Steven W. Eck sold 3,525 shares of the company’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the transaction, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Avantor

Several hedge funds have recently modified their holdings of AVTR. Jennison Associates LLC lifted its stake in Avantor by 113.0% during the 1st quarter. Jennison Associates LLC now owns 2,497,349 shares of the company’s stock valued at $63,857,000 after acquiring an additional 1,325,026 shares during the period. Swedbank AB acquired a new stake in Avantor during the 1st quarter worth about $2,707,000. Diversify Advisory Services LLC purchased a new position in shares of Avantor during the 1st quarter valued at about $908,000. BNP Paribas Financial Markets lifted its holdings in shares of Avantor by 42.4% in the 1st quarter. BNP Paribas Financial Markets now owns 309,394 shares of the company’s stock valued at $7,911,000 after buying an additional 92,098 shares during the period. Finally, William Blair Investment Management LLC boosted its stake in shares of Avantor by 44.6% in the first quarter. William Blair Investment Management LLC now owns 1,047,732 shares of the company’s stock worth $26,791,000 after buying an additional 322,985 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.